Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Back in December, Norway’s $1.5 trillion wealth fund, also known as the Norges Bank Investment Management (NBIM), urged Tesla to sign a collective agreement with trade union IF Metall. The NBIM’s stance in December was seen by Tesla skeptics as a sign that the fund may be stepping back from its support of the electric vehicle maker.
As per a recent report from Bloomberg News, however, the NBIM actually boosted its holdings in Tesla last year. The fund saw Tesla climb to its 11th largest holding by the end of 2023, with its stake rising to 0.98%, or about $7.7 billion. In the year prior, the NBIM held a 0.87% stake in the electric vehicle maker.
Tesla China's insurance registrations rise 9.4% to 12.8k in January's 4th week
Whales are piling on and in full control. This should be well over $700 by earnings
I have a Tesla 3 at a vacation home very far north. Christmas, -10 and no issues. It's parked outside. Best car for winter ever, climbs every hill in snow
Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ management will be attending and presenting at the following upcoming investor conferences:
Stifel Biotech Executive Summit
Format: Fireside chat
Presenter: Riad Sherif, MD, Chief Executive Officer
Presentation date and time: February 7, 2024 at 7:30 am MT (Mountain Time)
Location: Pendry Park City, Park City, Utah, USA
BioCapital Europe 2024
Format: Company presentation
Presenter: Sylvia Cheung, Chief Financial Officer
Presentation date and time: February 8, 2024 at 11:40 am CET (Central European Time)
Location: Hotel Sofitel Legend The Grand Amsterdam, Amsterdam, Netherlands
The Company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.
Tesla To Spend Billions of Dollars On NVIDIA AI Hardware This Year, Also Plans on Buying AMD Chips
The governor is correct that this is a Dojo Supercomputer, but $500M, while obviously a large sum of money, is only equivalent to a 10k H100 system from Nvidia.
Tesla will spend more than that on Nvidia hardware this year. The table stakes for being competitive in AI are at least several billion dollars per year at this point.
Elon Musk
The governor is correct that this is a Dojo Supercomputer, but $500M, while obviously a large sum of money, is only equivalent to a 10k H100 system from Nvidia.
Tesla will spend more than that on Nvidia hardware this year. The table stakes for being competitive in AI are at least several billion dollars per year at this point.
Elon Musk
Couldn't agree more
Consolidating nicely before next move up
Cathie bought $32.5M of $TSLA today
$175-180
Oculis Holding AG (Nasdaq: OCS) (“Oculis” or “the Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced it will host an in-person R&D Day in Midtown, New York City, on Wednesday, February 28, 2024 from 9:00 AM to 11:00 AM ET. Please click here to attend the event either in-person or virtually. Location details for in-person attendance will be provided upon registration.
The event will showcase two of Oculis’ clinical programs:
OCS-01, a high concentration dexamethasone eye drop formulation developed with the proprietary OPTIREACH® technology to reach the retina, in Diabetic Macular Edema (DME): presentations will include an update on the OCS-01 development programs and a discussion of how OCS-01 could transform the current treatment paradigm by addressing the pre-invasive patient segment with an early intervention, and the segment of patients with inadequate response to current standard of care, from:
David Boyer, M.D. (Keck School of Medicine, University of Southern California, and Retina Vitreous Associates Medical Group)
Arshad M. Khanani, M.D., M.A. FASRS (Reno School of Medicine, University of Nevada, and Sierra Eye Associates)
Ramin Tadayoni, M.D., Ph.D. (Université Paris Cité, Lariboisière & Rothschild Foundation Hospitals, Paris, President of EURETINA)
Elizabeth Yeu, M.D. (Eastern Virginia Medical School, Virginia Eye Consultants, and President of ASCRS)
OCS-02, a TNFa inhibitor licaminlimab eye drop formulation developed with a proprietary antibody fragment technology to treat ocular inflammation, in Dry Eye Disease (DED): presentations will cover the unmet medical need, TNF inhibition mechanism of action to manage ocular inflammation, the potential for a precision medicine approach in DED, and an overview of the licaminlimab (OCS-02) RELIEF trial program, from:
Christophe Baudouin, M.D. Ph.D. (Quinze-Vingts National Ophthalmology Hospital, Paris)
Eric Donnenfeld, M.D. (New York University)
Anat Galor, M.D., M.S.P.H. (Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami)
George Ousler, M.S. (Ora, Inc.)
Victor Perez, M.D. (Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami)
The topic discussions will be moderated by Pravin Dugel, M.D. (Director, Oculis’ Board) and Riad Sherif, M.D. (Chief Executive Officer, Oculis).
In addition, management will provide a brief 2023 review and business outlook for 2024. Live question and answer sessions will be conducted during the event.
Optimus to customers next year very probable
#Tesla is an AI/Robotics Company $TSLA, not a car company!
- Elon Musk -
Shorts will burn here, momentum upwards
That will not age well
I wouldn't short this monster
$1k by end February
Reuters reports that "Tesla has told suppliers it wants to start production of a new mass market electric vehicle codenamed "Redwood" in mid-2025, according to four people familiar with the matter, with two of them describing the model as a compact crossover."
"Tesla sent "requests for quotes," or invitation for bids for the "Redwood" model, to suppliers last year, and forecast weekly production volume of 10,000 vehicles, two of the sources said.
Production would begin in June 2025, three of the sources said. All spoke on condition of anonymity because the matter is confidential."
It's a realistic timeline and indicates that the design for the Redwood model is mainly finished.
Although not yet officially confirmed, it is not news that Tesla is working on its compact car and a mid-2025 delivery date is realistic.
It will be the opposite today, we all know what's coming
Cantor Fitzgerald new target: $775
Current option action tells us something bullish is on the horizon and good possibility for short squeeze
This will not age well come Thursday
That won't age well
Tesla 3 Highlander launched inn the US!
https://www.tesla.com/model3/
Doesn't sound like EV is being subsidized based on prices
Taxes are higher on an EV such as Tesla. Canada has gone full communist
I'd move
Fake news! You can lease a brand new Tesla's Model 3 for $329/month. You can buy it for $35K or less depending on State.
2022 X plaid and Model 3 here
Cathie Wood Is Buying Up Tesla (TSLA) Stock
TSLA stock is up on Wood purchases
1h ago · By William White, InvestorPlace Writer
Tesla (TSLA) stock is up on Thursday after Cathie Wood bought shares.
The investors acquired 216,000 shares of TSLA for about $25.09 million.
Cathie Wood Buys Tesla Shares Just as Wall Street’s View Dims
6
Abhishek Vishnoi
Wed, January 3, 2024 at 11:31 PM EST·2 min read
Cathie Wood Buys Tesla Shares Just as Wall Street’s View Dims
In this article:
TSLA
-4.01%
(Bloomberg) -- Cathie Wood has started buying Tesla Inc. shares after selling them for most of last year. Her purchases come at a time when Wall Street’s outlook on the electric-vehicle maker is darkening rapidly.
Most Read from Bloomberg
Confidential Jeffrey Epstein Documents Unsealed by New York Court
Fed Sees Rates Staying High for Some Time With Cuts Eyed in 2024
Saving the Panama Canal Will Take Years and Cost Billions, If It’s Even Possible
Tech Stocks Log Four-Day Losing Streak, Bonds Rise: Markets Wrap
Iran Blasts That Killed Nearly 100 Add to Mideast Tensions
Funds operated by Wood’s firm Ark Investment Management LLC have bought about 216,000 shares of the company over investments made on Dec. 20 and Jan. 3, according to Ark’s daily trading data compiled by Bloomberg. Before the current buying streak, Ark had largely sold shares in the EV maker for three straight quarters.
Analysts’ overall view on Tesla is fast deteriorating as an EV slowdown looms, government incentives are drying up and Chinese rival BYD Co.’s cheaper models are threatening its leadership position in electric cars. Tesla shares fell 4% to close at $238.45 on Wednesday.
The 12-month forward consensus profit estimate for Tesla has dropped more than 20% over the past year compared to a rise of 6% in the same metric for the S&P 500 Index, according to data compiled by Bloomberg. The EV maker’s consensus analyst rating is near its lowest score in almost two years.
While the industry’s growth is expected to slow down and China’s is on track to become the world’s largest passenger car exporter, Wood believes Tesla is primed to grab more market share as peers like General Motors Co. and Ford Motor Co. step back from their EV plans due to profitability concerns.
“There is more share for Tesla and others who choose to go for it,” Wood said on Bloomberg TV last week.
Ark’s analysis of Tesla yields a price estimate of $2,000 per share in 2027, while its bull and bear cases come in at $2,500 and $1,400 per share, respectively, the investment management firm reiterated in a year-ender email to its subscribers. Ark’s flagship fund has risen 59% over the last 12 months compared to a gain of 51% for the Nasdaq 100 Index.
Hard to time but Tesla and Nvda severely oversold
Smart
In my crystal ball
Tesla will deliver 3M cars in 24? DB have zero clue
the reverse happens when you don't expect it, I say buy down here